Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Safe New Treatment Combination For Head And Neck Cancer Patients
Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI). The results were disclosed at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) on May 30 in Orlando, Fla.
generic viagra online
Multivitamins In Pregnancy Reduce Risk Of Low Birth Weights
Prenatal multivitamin supplements are associated with a significantly reduced risk of babies with a low birth weight compared with prenatal iron-folic acid supplementation, found a new study in the Canadian Medical Association Journal (CMAJ).
News of the day
Melatonin - The Fountain Of Youth?
Melatonin can slow down the effects of aging. A team at laboratoire Arago in Banyuls sur Mer (CNRS / Universitç© Pierre et Marie Curie) has found that a treatment based on melatonin can delay the first signs of aging in a small mammal. These results appeared in the journal PLoS ONE on 15 June 2009.
Endocrinology

Meda: Onsolis Receives FDA Approval

The U.S. Food and Drug Administration (FDA) has approved Onsolis (fentanyl buccal soluble film). This new and patented product is indicated for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Onsolis uses a unique delivery system designed to give rapid and reliable delivery of fentanyl. The product consists of a small dissolvable disc for application of fentanyl to the buccal (inner lining of cheek) membranes. The product is unique and offers an important step to a better pain treatment of cancer patients. "I"m very pleased that Onsolis has been approved for marketing in the U.S. For Meda in the U.S., we get yet another important product addition. The interest among specialists for this new technology is significant, and we are making preparations for product launch during the fourth quarter of 2009. The registration procedures for Onsolis in other key markets are progressing according to plan", said Anders Lç¶nner, CEO Meda. Meda has, in close collaboration with the FDA and Meda"s development partner BioDelivery Sciences Inc, developed the REMS (Risk Evaluation and Mitigation Strategy) program for Onsolis. This REMS program has also been approved by the FDA. MEDA AB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009